[{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Academy of Neurology Publishes ProMIS Neurosciences\u2019 Abstracts on Novel Antibody Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ProMIS Neurosciences"},{"orgOrder":0,"company":"Almac Group","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Taps Almac in Neurodegenerative Drug Discovery Deal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Almac Group"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Skyhawk Therapeutics Expands its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Skyhawk Therapeutics"},{"orgOrder":0,"company":"Icagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$274.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Icagen\u2019s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Icagen"},{"orgOrder":0,"company":"Concept Life Sciences","sponsor":"AstronauTx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Concept Life Sciences"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,230\u202c.0 million","upfrontCash":"$20.0 million","newsHeadline":"Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evox Therapeutics"},{"orgOrder":0,"company":"University of Oslo","sponsor":"BioArctic AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"University of Oslo"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Twist Bioscience"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evox Therapeutics"},{"orgOrder":0,"company":"X-Chem","sponsor":"Orexia Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem Announces Achievement of Milestone In Orexia Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"X-Chem"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nura Bio"},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurasic Therapeutic Launched to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Neurasic Therapeutic"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Addex Therapeutics"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LUCA Science"},{"orgOrder":0,"company":"Libra Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"Libra Therapeutics Launches with $29 Million Series A to Develop Novel Therapeutics for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Libra Therapeutics"},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Invetx"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Knopp Biosciences LLC"},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Insitro"},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Lacerta Therapeutics"},{"orgOrder":0,"company":"Faze Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Faze Medicines"},{"orgOrder":0,"company":"Locanabio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel Rnatargeted Gene Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Locanabio"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$161.5 million","upfrontCash":"$7.0 million","newsHeadline":"Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen\u2019s Discovery Technology to Target Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"LifeArc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metrion Biosciences and LifeArc Further Extend Neuroscience-focused Ion Channel Drug Discovery Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Metrion Biosciences"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Wren Therapeutics Announces Financing of \u00a312.4 Million (c. $17.0 Million)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Wren Therapeutics"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accure Therapeutics Publishes Pivotal Preclinical Efficacy Study in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Accure Therapeutics"},{"orgOrder":0,"company":"UC Berkeley","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"Weill Neurohub Joins with Genentech, Roche to Advance Neuroscience Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"UC Berkeley"},{"orgOrder":0,"company":"Amathus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amathus Therapeutics Signs Strategic Collaboration with Merck to Develop Treatments for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Amathus Therapeutics"},{"orgOrder":0,"company":"DZNE","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dzne and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"DZNE"},{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$81.5 million","upfrontCash":"Undisclosed","newsHeadline":"StrideBio Announces Closing of $81.5M Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"StrideBio"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Confo Therapeutics"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Avoro Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scribe Therapeutics Raises $100M Series B Financing to Further Develop \u201cCRISPR by Design\u201d Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Scribe Therapeutics"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"BioArctic AB"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$3,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream and Takeda Expand Collaborative Research and License Agreement to Develop Peptide Drug Conjugates for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"PeptiDream"},{"orgOrder":0,"company":"Complix","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Complix"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission and AbbVie deal in Alzheimer\u2019s and Parkinson Reaches Next Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mission Therapeutics"},{"orgOrder":0,"company":"1910 Genetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"1910 Genetics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"$279.0 million","upfrontCash":"$9.0 million","newsHeadline":"Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bristol Myers Squibb"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"bit.bio Raises in Excess of $100 Million in First Close of Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bit Bio"},{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biorchestra"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"SBI Investment Co","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Raises $2Million (\u00a5200M Yen) in Seed Funding Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Veneno Technologies"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Hooke Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Pasithea Therapeutics"},{"orgOrder":0,"company":"Celeris Therapeutics","sponsor":"Pace Ventures Enigma","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"CelerisTx Announces $4.4m Financing to Advance Pipeline of Novel Proximity Inducing Compound","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Celeris Therapeutics"},{"orgOrder":0,"company":"Medicines Discovery Catapult","sponsor":"Alchemab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab Extends Partnership with Medicines Discovery Catapult to Bolster Collaborative Approach to Tackle Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Medicines Discovery Catapult"},{"orgOrder":0,"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"HitGen"},{"orgOrder":0,"company":"Centogene","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Centogene Announces Expansion of Data Access and Collaboration Agreement With Pfizer","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Centogene"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cyclica"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"IAMA Therapeutics"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"OrganoTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vyant Bio and Organo Therapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Vyant Bio"},{"orgOrder":0,"company":"Iktos","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Iktos"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Halia Therapeutics"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Shape Therapeutics"},{"orgOrder":0,"company":"PharmEnable","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmEnable Announces Multi-Target Collaboration with Denali Therapeutics in Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmEnable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"IGC Pharma"},{"orgOrder":0,"company":"Vitalunga","sponsor":"Hebrew University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Startup Vitalunga Creates Novel Oral Drug to Enable Disease-free Aging; Pre-clinical Studies Expected to Begin in Near Future","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Vitalunga"},{"orgOrder":0,"company":"EditForce","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"$145.7 million","upfrontCash":"Undisclosed","newsHeadline":"EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"EditForce"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purespring Therapeutics And SwanBio Therapeutics Announce Licensing Agreement for Use of FunSel Screening Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Purespring Therapeutics"},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Lacerta Therapeutics"},{"orgOrder":0,"company":"Metabolon\u202f","sponsor":"BioFINDER","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Metabolon\u202f"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research From the University of Birmingham, U.K., Identifies New Treatment Target for CNS Injury and Neurological Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"University of Birmingham"},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"LAPAM","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"NeuShen Therapeutics Closes Pre-A Financing with ~$20M","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"NeuShen Therapeutics"},{"orgOrder":0,"company":"Cajal Neuroscience","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cajal Neuroscience"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bit Bio"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai And Washington University School Of Medicine In St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming To Create New Therapies For Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eisai"},{"orgOrder":0,"company":"PrecisionLife","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"PrecisionLife"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"},{"orgOrder":0,"company":"Sironax","sponsor":"X-Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sironax"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Schrodinger","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otsuka and Schr\u00f6dinger Announce Single-Target, Drug Discovery Collaboration in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"VectorY"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem\u2019s Tech Transfer Company, Yissum","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Clearmind Medicine"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,754.0 million","upfrontCash":"$54.0 million","newsHeadline":"Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER AAV Capsids for Gene Therapy Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Voyager Therapeutics, Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Luxna Announces Technology License Agreement With Takeda","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Luxna Biotech"},{"orgOrder":0,"company":"Aquinnah Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquinnah Pharmaceuticals Announces Collaboration With Roche To Advance New Therapies for ALS and Other Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Aquinnah Pharmaceuticals"},{"orgOrder":0,"company":"Cardiff University","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Cardiff University"},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"LifeArc Ventures","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Ventures Invests in Maxion Therapeutics to Drive Antibody Development for Previously Untreatable Ion Channel And GPCR-Driven Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Maxion Therapeutics"},{"orgOrder":0,"company":"AbCheck","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCheck"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion and LISCure Biosciences Announce Strategic Collaboration to Develop Novel Microbiome Treatment for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"LISCure Biosciences"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Secarna Pharma"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Confo Therapeutics"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo\u24c7 for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"JCR Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$505.5 million","upfrontCash":"Undisclosed","newsHeadline":"Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"JCR Pharmaceuticals"},{"orgOrder":0,"company":"Modulo Bio","sponsor":"Initialized Capital","pharmaFlowCategory":"D","amount":"$8 million","upfrontCash":"Undisclosed","newsHeadline":"Modulo Bio Launches to Map the Neuroimmune System and Develop Treatments for Neurodegenerative Diseases, Starting With ALS and FTD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Modulo Bio"},{"orgOrder":0,"company":"Selvita S.A","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"POLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Selvita S.A"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the collaboration, University of Oxford and Selvita will advance potential therapeutics in the area of Parkinson's disease and have developed promising prototype compounds that efficiently promote the clearance of alpha-synuclein aggregates.
The fundings will be used to accelerate the development of Modulo’s first therapeutic program and its Modulo Neuroimmune Platform, to develop effective treatments for neurodegenerative disease.
Under the agreement, the two companies will begin research and development of new treatments using the J-Brain Cargo®, blood-brain barrier (“BBB”) penetration technology, in combination with an undisclosed effector molecule for the treatment of a neurodegenerative disease.
Under the terms of the agreement, Confo will lead the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Under the collaboration, the companies will work together to generate novel Antisense Oligonucleotide therapies directed at targets that play a critical role in diseases of the Central Nervous System.
Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target for peripheral neural response.
Under the agreement, Celltrion and LISCure intend to develop, oral LBPs, microbiome-based therapies, for Parkinson's disease. LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases based on its platform technology.
The funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class for the treatment of Autoimmune diseases and Chronic pain.
Under the terms of the agreement, scientists at the MDI and Astex will collaborate to carry out drug discovery research against a chosen lysosomal target with the aim to identify and optimise compounds that modulate its activity to treat neurodegenerative diseases.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
